儿童神经母细胞瘤治疗市场 - 全球产业规模、份额、趋势、机会和预测，按治疗类型、按最终用户、按地区和竞争细分，2020-2030 年预测

2024 年全球儿童神经母细胞瘤治疗市场价值为 14.5 亿美元，预计在预测期内将出现令人印象深刻的增长，到 2030 年的复合年增长率为 8.58%。儿童神经母细胞瘤是一种主要影响幼儿的癌症，通常发生在婴儿和幼儿身上，但偶尔也会发生在年龄较大的儿童身上。它起源于身体各部位的未成熟神经细胞（神经母细胞），最常见的是位于肾臟顶部的肾上腺。然而，它也可能出现在交感神经系统的其他部位，包括胸部、腹部和骨盆。神经母细胞瘤的症状取决于肿瘤的大小、位置以及是否扩散。常见症状可能包括腹部肿胀，疼痛，肿块或肿块，体重减轻，食慾不振，骨痛，烦躁，发烧和眼睛变化（如眼睑下垂或瞳孔大小不等）。诊断通常需要结合多种影像检查，例如超音波、CT 扫描和 MRI 扫描，以定位和评估肿瘤。还可以进行活检和骨髓抽吸以确认诊断并确定肿瘤的侵袭性。例如，根据美国临床肿瘤学会 (ASCO) 的数据，神经母细胞瘤是美国儿童第三大常见癌症，占所有儿童癌症病例的 6%。预计这种高发病率将推动对先进有效治疗方案的需求，以改善被诊断患有神经母细胞瘤的儿童的治疗结果。

主要市场驱动因素

儿童神经母细胞瘤发生率上升

主要市场挑战

毒性和长期影响

主要市场趋势

尽量减少辐射

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：全球儿童神经母细胞瘤治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依治疗类型（化疗、免疫疗法、放射疗法等）
  • 按最终使用者（医院、专科诊所和其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：亚太地区儿童神经母细胞瘤治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 7 章：欧洲儿童神经母细胞瘤治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 8 章：北美儿童神经母细胞瘤治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 9 章：南美洲儿童神经母细胞瘤治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲儿童神经母细胞瘤治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 13 章：全球儿童神经母细胞瘤治疗市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章： 大环境分析

第 16 章：竞争格局

• United Therapeutics Corporation,
• APEIRON Biologics AG
• Baxter International Inc.,
• Cell Ectar Biosciences Inc.
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• Bayer AG
• Provectus Biopharmaceuticals Inc.
• Sartorius AG
• , Amgen Inc.

第 17 章：策略建议

第18章调查会社について・免责事项

Global Pediatric Neuroblastoma Treatment Market was valued at USD 1.45 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.58% through 2030. Pediatric Neuroblastoma is a type of cancer that primarily affects young children, usually occurring in infants and toddlers but occasionally in older children. It arises from immature nerve cells (neuroblasts) that are found in various areas of the body, most commonly in the adrenal glands, which sit on top of the kidneys. However, it can also develop in other parts of the sympathetic nervous system, including the chest, abdomen, and pelvis. The symptoms of neuroblastoma vary depending on the tumor's size, location, and whether it has spread. Common symptoms may include abdominal swelling, pain, a lump or mass, weight loss, loss of appetite, bone pain, irritability, fever, and changes in the eyes (such as drooping eyelids or unequal pupil size). Diagnosis often involves a combination of imaging tests, such as ultrasound, CT scans, and MRI scans, to locate and evaluate the tumor. Biopsy and bone marrow aspiration may also be performed to confirm the diagnosis and determine the tumor's aggressiveness. For instance, according to the American Society of Clinical Oncology (ASCO), neuroblastoma is the third most prevalent cancer among children in the U.S., representing 6% of all childhood cancer cases. This high incidence is expected to drive demand for advanced and effective treatment options to improve outcomes for children diagnosed with neuroblastoma.

Key Market Drivers

Rising Incidence of Pediatric Neuroblastoma

Growing awareness among healthcare providers and the public about the signs and symptoms of pediatric neuroblastoma has led to earlier diagnosis. As more cases are detected at an earlier stage, there is a greater need for timely and effective treatment. For instance, according to a 2025 study titled Global and Regional Trends in Paediatric Neuroblastoma Incidence and Mortality, 1990-2021: An Inequality and Projection Analysis, the global age-standardized death rate for pediatric neuroblastoma increased from 0.19 (95% UI, 0.16-0.23) in 1990 to 0.21 (95% UI, 0.14-0.28) per 100,000 population in 2021, with an estimated annual percentage change (EAPC) of 0.2. Regionally, mortality and incidence rates were highest in low-to-middle Social Development Index (SDI) regions, while Oceania recorded the lowest rates. Improved diagnostic techniques, such as genetic testing and advanced imaging, have made it easier to identify neuroblastoma cases accurately. This early detection allows for prompt intervention and treatment. The general growth in the global population, including the pediatric population, naturally leads to an increase in the number of neuroblastoma cases. While the exact causes of neuroblastoma remain unclear, some environmental and genetic factors may contribute to its development. As these factors continue to be studied, it may become possible to identify at-risk populations more effectively. The rising incidence of neuroblastoma has prompted increased research into potential treatments. Clinical trials and research efforts are essential in developing new therapies, which, in turn, drive the demand for Pediatric Neuroblastoma Treatment. The development of more effective and less toxic treatment options has improved the chances of successful outcomes for neuroblastoma patients. This has increased the demand for these treatments as they become more accessible. Advances in supportive care for pediatric cancer patients have improved overall treatment experiences and outcomes. As the quality of care continues to improve, more families seek treatment for their children. Improved access to healthcare services in various regions around the world means that more children with neuroblastoma are receiving appropriate treatment. This factor will help in the development of the Global Pediatric Neuroblastoma Treatment Market.

Key Market Challenges

Toxicity and Long-Term Effects

The standard treatments for pediatric neuroblastoma, which often include chemotherapy, radiation therapy, and surgery, can cause severe side effects in young patients. These treatments may damage healthy tissues and organs in addition to targeting cancer cells. The toxicity can result in short-term complications, such as nausea, fatigue, and hair loss, which can significantly impact a child's quality of life during treatment. Beyond the immediate treatment period, pediatric neuroblastoma survivors may face long-term health issues and late effects of treatment. These can include developmental delays, growth problems, hormonal imbalances, organ dysfunction, and an increased risk of secondary cancers. Monitoring and managing these long-term health issues require ongoing medical care and support. The toxicity and long-term effects of treatment can affect a child's physical and emotional well-being, as well as their ability to engage in normal childhood activities. This can have a lasting impact on their quality of life and overall development. Pediatric neuroblastoma and its treatment can take a toll on the psychological well-being of both patients and their families. Coping with treatment-related toxicity and long-term effects can be emotionally challenging, requiring psychosocial support and mental health services. Pediatric neuroblastoma survivors often require specialized survivorship care to address the unique health issues that may arise years after treatment. Access to comprehensive follow-up care and support services is essential to managing these long-term effects effectively. Finding the right balance between delivering effective treatment and minimizing toxicity is a complex challenge in pediatric neuroblastoma care. Oncologists must make treatment decisions that maximize the chances of a cure while minimizing potential harm.

Key Market Trends

Minimizing Radiation

Radiation therapy, while effective in treating neuroblastoma, can cause long-term side effects, especially in pediatric patients. These side effects may include growth abnormalities, developmental delays, and an increased risk of secondary cancers. Minimizing radiation aims to mitigate these risks. Innovations in radiation therapy techniques, such as intensity-modulated radiation therapy (IMRT) and proton therapy, allow for more precise targeting of cancer cells while sparing nearby healthy tissues. This precision reduces the potential for collateral damage and long-term toxicity. Radiation oncologists are increasingly tailoring treatment plans to each patient's specific needs and tumor characteristics. This individualized approach ensures that the minimum necessary radiation dose is used while maximizing therapeutic benefits. Minimizing radiation is often achieved through combination therapies. For instance, using chemotherapy or surgery to shrink tumors before radiation may allow for lower radiation doses and less toxicity. Risk stratification of neuroblastoma patients helps determine the appropriate level of treatment intensity. Low-risk patients may receive less aggressive therapy, including reduced radiation, to minimize long-term effects. Ongoing clinical trials are exploring novel treatment approaches that may reduce the reliance on radiation therapy or allow for lower radiation doses. These trials aim to maintain or improve treatment outcomes while minimizing toxicity. As more children with neuroblastoma survive into adulthood, there is a growing emphasis on long-term survivorship care. Minimizing radiation plays a role in reducing the late effects of treatment and improving the quality of life for survivors.

Key Market Players

• United Therapeutics Corporation
• APEIRON Biologics AG
• Baxter International Inc.
• Cell Ectar Biosciences Inc.
• Pfizer Inc.
• Bayer AG
• Provectus Biopharmaceuticals Inc.
• Sartorius AG
• Amgen Inc.
• F. Hoffmann-La Roche AG

Report Scope:

In this report, the Global Pediatric Neuroblastoma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Neuroblastoma Treatment Market, By Treatment Type:

• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Others

Pediatric Neuroblastoma Treatment Market, By End-User:

• Hospitals
• Specialty clinics
• Others

Pediatric Neuroblastoma Treatment Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Neuroblastoma Treatment Market.

Available Customizations:

Global Pediatric Neuroblastoma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pediatric Neuroblastoma Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy, and Others)
  • 5.2.2. By End-User (Hospitals, Specialty Clinics and Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Pediatric Neuroblastoma Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By End-User
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Pediatric Neuroblastoma Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By End-User
  • 6.3.2. India Pediatric Neuroblastoma Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By End-User
  • 6.3.3. Australia Pediatric Neuroblastoma Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By End-User
  • 6.3.4. Japan Pediatric Neuroblastoma Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment Type
      • 6.3.4.2.2. By End-User
  • 6.3.5. South Korea Pediatric Neuroblastoma Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment Type
      • 6.3.5.2.2. By End-User

7. Europe Pediatric Neuroblastoma Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By End-User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Pediatric Neuroblastoma Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By End-User
  • 7.3.2. Germany Pediatric Neuroblastoma Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By End-User
  • 7.3.3. Spain Pediatric Neuroblastoma Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By End-User
  • 7.3.4. Italy Pediatric Neuroblastoma Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By End-User
  • 7.3.5. United Kingdom Pediatric Neuroblastoma Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By End-User

8. North America Pediatric Neuroblastoma Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By End-User
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Pediatric Neuroblastoma Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By End-User
  • 8.3.2. Mexico Pediatric Neuroblastoma Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By End-User
  • 8.3.3. Canada Pediatric Neuroblastoma Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By End-User

9. South America Pediatric Neuroblastoma Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By End-User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pediatric Neuroblastoma Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By End-User
  • 9.3.2. Argentina Pediatric Neuroblastoma Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By End-User
  • 9.3.3. Colombia Pediatric Neuroblastoma Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By End-User

10. Middle East and Africa Pediatric Neuroblastoma Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By End-User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pediatric Neuroblastoma Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By End-User
  • 10.3.2. Saudi Arabia Pediatric Neuroblastoma Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By End-User
  • 10.3.3. UAE Pediatric Neuroblastoma Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Pediatric Neuroblastoma Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. United Therapeutics Corporation,
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. APEIRON Biologics AG
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Baxter International Inc.,
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. Cell Ectar Biosciences Inc.
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Pfizer Inc.
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. F. Hoffmann-La Roche AG
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Bayer AG
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Provectus Biopharmaceuticals Inc.
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Sartorius AG
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10., Amgen Inc.
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer